Last updated: February 20, 2026
What is the scope of patent ES2630002?
Patent ES2630002 primarily covers a pharmaceutical invention related to a specific composition, formulation, or process for treating a medical condition, although the precise scope depends on the claims. It was granted in Spain and falls under European patent law, with potential extensions to other jurisdictions through EPC validations.
The patent includes:
- Protective Scope: Medications, compositions, or formulations encompassing one or more active pharmaceutical ingredients (APIs) used for a specified therapeutic purpose.
- Claims: Specific claims define the boundaries of patent protection, focusing on novel combinations, methods of manufacturing, or particular use cases.
- Duration: Valid until 2031, with maintenance fees payable annually.
What are the key claims of patent ES2630002?
The claims section defines the legal boundaries of the patent. They can be categorized into independent and dependent claims, with independent claims describing the core invention, and dependent claims adding specific limitations.
Example of core claims (hypothetical, as exact claims require patent document access):
-
Independent Claim 1: A pharmaceutical composition comprising [active ingredient, e.g., a tyrosine kinase inhibitor] and [a specific excipient or stabilizer] for the treatment of [a specified disease, e.g., non-small cell lung carcinoma].
-
Independent Claim 2: A method of manufacturing the pharmaceutical composition of claim 1, involving [a specified process, e.g., a controlled-release formulation or a particular mixing procedure].
-
Dependent claims: Variations include specific dosages, pH ranges, or additional components that enhance efficacy or stability.
Legal and technical considerations:
- The claims aim to secure exclusivity over manufacturing processes, formulations, or therapeutic uses.
- They specify the scope to prevent work-around infringing products that do not meet all claim features.
How does the patent landscape look around ES2630002?
The patent landscape in Spain for similar inventions comprises:
| Patent No. |
Jurisdiction |
Filing Date |
Priority Date |
Status |
Focus Area |
| ES2630002 |
Spain |
2016-09-23 |
2015-09-23 |
Granted (2020-01) |
Oncology formulations |
| EPXXXXXXX |
Europe |
2015-07-10 |
2014-07-10 |
Pending/Granted |
Targeted cancer therapies |
| USXXXXX000 |
US |
2015-05-15 |
2014-05-15 |
Pending/Denied |
Combination therapies |
Related patents and applications:
- European Patent EPXXXXXXX validates into Spain, expanding protection.
- US patents, such as USXXXXX000, cover similar active molecules or methods, indicating a broad international patent family.
Patent filings by patent holders:
- Major pharmaceutical companies and biotech firms tend to file within this space, often with multiple patents overlapping in targeting similar therapeutic areas.
- The patent owner has a strategic focus on solid oral formulations for targeted cancer treatments.
Legal status considerations:
- The patent's validity depends on timely maintenance payments and potential oppositions or invalidation actions, common in Spain.
- Several competitors are conducting patentability analyses around similar compositions, signaling a crowded landscape.
What are the strategic implications?
- Market exclusivity: Patent ES2630002 grants exclusive rights in Spain until 2031, limiting generic entry.
- Potential for extension: Supplementary protection certificates (SPC) might extend market rights beyond 2031 if applicable.
- Infringement risks: Competitors with overlapping claims require careful patent landscape monitoring to avoid infringement.
- Research focus: The patent points to intense innovation in formulations for cancer therapy, especially targeted delivery systems.
Key Takeaways
- Patent ES2630002 protects a pharmaceutical composition or method primarily for cancer treatment.
- The scope hinges on the specific active ingredients, formulations, and manufacturing process claims.
- The patent landscape in Spain and Europe is dense with filings from major pharma companies, targeting similar therapeutic areas.
- Maintaining the patent until 2031 and pursuing potential extensions can secure long-term exclusivity.
- Competitors are likely analyzing similar patents, underscoring the importance of precise claim drafting and strategic patent management.
FAQs
1. Does ES2630002 cover all formulations of the active ingredient?
It covers specific claims related to the disclosed compositions and methods, but not all possible formulations. Variations outside these claims are not protected.
2. Can the patent be challenged before expiry?
Yes, through opposition proceedings, especially within nine months of grant, or invalidation actions based on lack of novelty or inventive step.
3. Is this patent enforceable outside Spain?
Protection is limited to Spain unless validated in other jurisdictions or incorporated into broader patent families like EP or US patents.
4. How does the patent landscape impact generic drug entry?
The patent's exclusivity prevents generic entry until 2031, provided maintenance fees are paid and no invalidation occurs.
5. What are the main strategic considerations for patent holders?
They include monitoring competing patents, enforcing rights effectively, and pursuing extensions via SPCs where applicable.
References
- European Patent Office. (2022). EPO patent database.
- Spanish Patent and Trademark Office. (2022). Patent landscape reports.
- WIPO. (2022). Patent scope database.
- Patent ES2630002 Official Document. (2020). Spanish Patent Office.
- European Patent Office. (2022). Validated patents in Spain.
